Physician profile
Amanda Miller
NPI 1609274604
$2,219.94
in general payments reported to CMS, 2019-2025
14 companies · $550 in 2025
The $550 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $467 · 2023: $630 · 2024: $452 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $643.69 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $399.37 | 2022-2025 | |
| Lilly USA, LLC | $343.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $288.78 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $149.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $121.48 | 2023-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.15 | 2021-2024 | Ofev |
| Janssen Pharmaceuticals, INC | $64.43 | 2022 | |
| Exact Sciences Corporation | $63.73 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $19.42 | 2025 | |
| Genentech USA, INC. | $14.57 | 2021 | |
| Olympus America INC. | $14.14 | 2023 | Spiration Valve System |
| Esperion Therapeutics, INC. | $13.67 | 2021 | |
| Sumitomo Pharma America, INC. | $6.30 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.